九洲药业(603456) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,475,743,576.44, representing a decrease of 15.73% compared to the same period last year[4]. - The net profit attributable to shareholders for Q1 2024 was CNY 236,758,875.39, down 15.65% year-on-year[4]. - Basic and diluted earnings per share for Q1 2024 were both CNY 0.26, reflecting an 18.75% decrease from the same period last year[4]. - Total operating revenue for Q1 2024 was ¥1,475,743,576.44, a decrease of 15.7% compared to ¥1,751,242,194.31 in Q1 2023[16]. - Net profit for Q1 2024 was ¥236,172,887.54, a decline of 15.5% from ¥279,457,100.43 in Q1 2023[17]. - Earnings per share for Q1 2024 was ¥0.26, compared to ¥0.32 in Q1 2023[20]. Cash Flow - The net cash flow from operating activities was negative at CNY -136,464,671.63, a decline of 129.87% compared to the previous year, primarily due to a decrease in received payments[7]. - In Q1 2024, the net cash flow from operating activities was -$136,464,671.63, a significant decrease compared to $456,884,062.19 in Q1 2023[21]. - The total cash inflow from operating activities was $992,823,527.78, down from $2,098,706,912.05 in Q1 2023[21]. - The total cash outflow from operating activities was $1,129,288,199.41, down from $1,641,822,849.86 in Q1 2023[21]. - The cash flow from investing activities resulted in a net outflow of -$233,704,966.26, an improvement from -$332,225,561.14 in Q1 2023[21]. Assets and Liabilities - The total assets at the end of Q1 2024 amounted to CNY 12,249,806,417.65, an increase of 12.88% from the end of the previous year[4]. - As of March 31, 2024, the total assets of the company reached RMB 12,249,806,417.65, an increase from RMB 10,851,987,356.69 as of December 31, 2023, representing a growth of approximately 12.9%[12]. - Total liabilities as of Q1 2024 amounted to ¥3,514,004,192.37, an increase of 51.5% from ¥2,318,916,463.48 in Q1 2023[14]. - The total liabilities as of March 31, 2024, were not explicitly stated, but the short-term borrowings were reported at RMB 1,291,179,805.55[13]. Shareholder Information - The total equity attributable to shareholders at the end of Q1 2024 was CNY 8,664,450,376.14, an increase of 2.40% from the previous year[5]. - The total equity attributable to shareholders was ¥8,664,450,376.14 in Q1 2024, up from ¥8,461,133,056.22 in Q1 2023[14]. - The company had a total of 42,285 common shareholders at the end of the reporting period[8]. - The largest shareholder, Zhejiang Zhongbei Jiuzhou Group Co., Ltd., held 31.52% of the shares, totaling 283,518,812 shares[8]. - The total number of shares held by the top ten unrestricted shareholders was led by Zhejiang Zhongbei Jiuzhou Group Co., Ltd. with 283,518,812 shares[10]. Other Financial Metrics - The weighted average return on equity decreased to 2.77%, down 29.87 percentage points year-on-year[4]. - Research and development expenses for Q1 2024 were ¥64,871,910.84, a decrease of 17.7% from ¥78,769,888.33 in Q1 2023[16]. - The company reported a financial asset impairment loss of ¥33,969,218.86 in Q1 2024, compared to ¥16,342,638.65 in Q1 2023[17]. - Other comprehensive income after tax for Q1 2024 was ¥2,362,921.59, compared to ¥1,417,470.14 in Q1 2023[19]. - Non-recurring gains and losses for the period included government subsidies of CNY 5,529,960.92 and a loss from the disposal of non-current assets of CNY -2,214,288.46[6]. Executive Actions - The company plans to increase shareholding by key executives, with the president intending to purchase between RMB 12 million and RMB 15 million worth of shares within six months[11]. - The company reported a total of 64.33 million shares purchased by the president, representing 0.07% of the total share capital, with a total expenditure of RMB 12,049,400[11].